Results 91 to 100 of about 2,693 (166)

Effect of Imipenem-Relebactam on Sub-types of KPC in Klebsiella pneumoniae [PDF]

Open Forum Infectious Diseases, 2016
Katherine Young, Mary Motyl, Daniel Tatosian   +2 more
openaire   +1 more source

Determining the Activity of Imipenem/Relebactam Plus Aztreonam Against Constitutive <i>Pseudomonas</i>-Derived Cephalosporinase- and Metallo-β-Lactamase-Producing <i>Pseudomonas aeruginosa</i> in a Hollow Fiber Infection Model. [PDF]

Open Forum Infect Dis
O'Donnell JN, Moolick KE, Nahorniak AI, Gifford MJ, Young K, Lodise TP.   +5 more
europepmc   +1 more source

Antimicrobial Susceptibility of <i>Pseudomonas aeruginosa</i> from Elderly Patients in Intensive Care Units of United States Medical Centers (2021-2025). [PDF]

Antibiotics (Basel)
Sader HS, Mendes RE, Doyle TB, Winkler ML, Castanheira M.   +4 more
europepmc   +1 more source

<i>In vitro</i> activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan. [PDF]

JAC Antimicrob Resist
Yanagihara K, Tateda K, Doi Y, Takahashi S, Ohge H, Itahashi K, Okade H, Mikamo H.   +7 more
europepmc   +1 more source

Case Commentary: When one target is not enough-PBP3 insertions and target redundancy in <i>Escherichia coli</i>. [PDF]

Antimicrob Agents Chemother
Stellfox ME, Doi Y.
europepmc   +1 more source

Emergence of KPC-producing <i>Pseudomonas aeruginosa</i> in Spain: insights into an outbreak and resistance to the novel carbapenem/β-lactamase inhibitor combinations imipenem/relebactam and meropenem/vaborbactam. [PDF]

Antimicrob Agents Chemother
Pérez-Rodríguez G, Aja-Macaya P, González-Pinto L, Taltavull B, Tarriño-León M, Gallardo-García MdM, Blanco-Martín T, Rodríguez-Pallares S, Sánchez-Peña L, Moscoso M, Beceiro A, Oliver A, Bou G, Arca-Suárez J.   +13 more
europepmc   +1 more source

In Vitro Activity of Cefiderocol, Eravacycline, and Imipenem-Relebactam Against Multidrug-Resistant <i>Acinetobacter baumannii</i> Clinical Isolates. [PDF]

Antibiotics (Basel)
Bölükbaşı Y, Öngen B.
europepmc   +1 more source

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. [PDF]

Antimicrob Agents Chemother
Patel M, Nieddu G, DeRyke CA, Young K, Chen LF, Paschke A, Rizk ML, Gheyas F.   +7 more
europepmc   +1 more source

Effectiveness of imipenem-relebactam for multidrug-resistant <i>Pseudomonas aeruginosa</i> in pneumonia and bloodstream infections in the United States (MIRAGE). [PDF]

Antimicrob Agents Chemother
Wangchinda W, Wu JY, Abbo LM, Ackley R, Bartley P, Gilboa M, Harrington J, Jaffa R, Klatt ME, Kline EG, Kubat RC, Lepak AJ, McCreary EK, Miller WR, Pearson JC, Shah S, Tran TT, Vega A, Vendetti M, Yucel E, Pogue JM, Shields RK.   +21 more
europepmc   +1 more source

In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates. [PDF]

J Antimicrob Chemother
Patterson-Fahy K, Carter R, Bell SC, Evans IES, Burke AJ, Thomson RM.   +5 more
europepmc   +1 more source